A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

TAK-981

TAK-981 IV infusion.

DRUG

Pembrolizumab

Pembrolizumab IV infusion.

Trial Locations (52)

3010

Universitaetsspital Bern - Inselspital, Bern

8400

Kantonsspital Winterthur, Winterthur

8596

Kantonsspital Muensterlingen, Münsterlingen

10000

Klinicki bolnicki centar Zagreb, Zagreb

10461

Montefiore Einstein Cancer Center - BRANY - PPDS, The Bronx

15213

UPMC Hillman Cancer Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

20817

The Center for Cancer and Blood Disorders - PPDS, Bethesda

21000

University Hospital Centre Split, Split

22031

Virginia Cancer Specialists (Fairfax) - USOR, Fairfax

22908

University of Virginia Health System, Charlottesville

27514

University of North Carolina at Chapel Hill, Chapel Hill

30912

Georgia Cancer Center at Augusta University, Augusta

31000

Clinical Hospital Centre Osijek, Osijek

52100

General Hospital Pula, Pula

73104

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City

75390

University of Texas Southwestern Medical Center, Dallas

78229

START South Texas Accelerated Research Therapeutics, San Antonio

85258

HonorHealth, Scottsdale

92868

University of California Irvine Medical Center, Orange

94305

Stanford Cancer Institute (SCI), Stanford

97213

Providence Cancer Institute, Franz Clinic, Portland

310003

The First Affiliated Hospital, Zhejiang University School of Medicine - PPDS, Hangzhou

510060

Sun Yat-Sen University Cancer Center, Guangzhou

06520

Yale Cancer Center, New Haven

07960

Morristown Medical Center, Morristown

08901

Cancer Institute of New Jersey, New Brunswick

80530-010

Instituto de Oncologia Do Parana, Curitiba

98700-000

ONCOSITE Centro de Pesquisa Clinica Em Oncologia, Ijuí

90035-903

Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre

90610-000

Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre

14784-370

Fundacao Pio XII Hospital de Cancer de Barretos, Barretos

15090-000

Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto

30110-140

Cetus Hospital Dia Oncologia, Belo Horizonte

20230-230

INCA Instituto Nacional de Cancer, Rio de Janeiro

20941-150

Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Rio de Janeiro

Unknown

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

277-0882

National Cancer Center East, Kashiwa-Shi

104-0045

National Cancer Center Hospital, Chuo-Ku

The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Chuo-Ku

LV-1002

Pauls Stradins Clinical University Hospital, Riga

LV-1079

Riga East Clinical University Hospital Latvian Oncology Center, Riga

LT-50161

Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas

Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas

LT-08660

National Cancer Institute, Vilnius

80-214

Uniwersyteckie Centrum Kliniczne-Ul. Smoluchowskiego 17, Gdansk

85-796

Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz

90-302

Instytut Medyczny Santa Familia Sp. z o. o., Lodz

20-362

Specjalistyczna Praktyka Lekarska Slawomir Mandziuk, Lublin

10-357

Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn

60-569

Med-Polonia Sp. z o.o., Poznan

90-242

Centrum Terapii Wspolczesnej, Lodz

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY